Effect of leukocytapheresis therapy using a leukocyte removal filter in Crohn's disease

Internal Medicine

Volumn 38, Issue 2, 1999, Pages 102-111

  Kosaka, Tadashi ^a   Sawada, Koji ^a   Ohnishi, Kunio ^a   Egashira, Akimitsu ^a   Yamamura, Makoto ^a   Tanida, Noritoshi ^a   Satomi, Masamichi ^a   Shimoyama, Takashi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

CD4+CD45+; Cytokine; Human leukocyte antigen (HLA) DR; Lymphocytapheresis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD45 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2;

ADULT; ARTICLE; BLOOD; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; CROHN DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOLOGY; INSTRUMENTATION; LEUKAPHERESIS; MALE; METABOLISM; METHODOLOGY; MICROPORE FILTER; NUTRITIONAL STATUS; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD45; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; CROHN DISEASE; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; LEUKAPHERESIS; MALE; MICROPORE FILTERS; NUTRITIONAL STATUS; TREATMENT OUTCOME;

EID: 0033071539     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.102     Document Type: Article

References (34)

1. Morita N, Toki S, Hirohashi T, et al. Incidence and prevalence of inflammatory bowel disease in Japan: Nationwide epidemiological survey during the year 1991. J Gastroenterol 30 Suppl 8: 1-4, 1995.
2. Summers RW, Switz DM, Sessions JT Jr, et al. National cooperative Crohn's disease study: Results of drug treatment. Gastroenterology 77: 847-869, 1979.
3. Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin Pharmacokinet 1: 406-425, 1976.
4. Rasmussen SN, Binder V, Maier K, et al. Treatment of Crohn's disease with peroral 5-aminosalicylic acid. Gastroenterology 85: 1350-1353, 1983.
5. Brooke BN, Cave DR, King DW. Place of azathioprine for Crohn's disease. Lancet 1: 1041-1042, 1976.
6. Fischer JE, Foster GS, Abel RM, Abbott WM, Ryan JA. Hyperalimentation as primary therapy for inflammatory bowel disease. Am J Surg 125: 165-175, 1973.
7. Hirakawa H, Fukuda Y, Tanida N, Hosomi M, Shimoyama T. Home elemental enterai hyperalimentation (HEEH) for the maintenance of remission in patients with Crohn's disease. Gastroenterol Jpn 28: 379-384, 1993.
8. Sawada K, Malchesky PS, Nosé Y. Available removal systems: Slate of the art. Curr Stud Hematol Blood Transfus 57: 51-113, 1990.
9. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 30: 322-329, 1995.
10. Amano K, Fujimoto K, Amano K, et al. Filter leukapheresis and immune related disease. Jpn J Apheresis 13: 61-64, 1994.
11. Sawada K. Ohnishi K, Kosaka T, et al. Exacerbated autoimmune hepatitis successfully treated with leukocytapheresis and bilirubin adsorption therapy. J Gastroenterol 32: 689-695, 1997.
12. Holdstock GE, Fisher JA, Hamblin TJ, Loehry C. Plasmapheresis in Crohn's disease. Digestion 19: 197-201, 1979.
13. Bicks RO, Groshart KD. The current status of T-lymphocyte apheresis (TLA) treatment of Crohn's disease. J Clin Gastroenterol 11: 136-138, 1989.
14. Lerebours E, Bussel A, Modigliani R, et al. Treatment of Crohn's disease by lymphocyte apheresis: A randomized controlled trial. Grouped Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 107: 357-361, 1994.
15. Singleton JW, Law DH, Kelley ML Jr, Mekhjian HS, Sturdevant RA. National Cooperative Crohn's Disease Study: Adverse reactions to study drugs. Gastroenterology 77: 870-882, 1979.
16. Hawthorne AB, Hawkey CJ. Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapy. Drugs 38: 267-288, 1989.
17. Takenaka Y. Lymphocytapheresis. Artif Organs 20: 914-916, 1996.
18. Sawada K, Ohnishi K, Kosaka T, et al. Leukocytapheresis with leukocyte removal filter as new therapy for ulcerative colitis. Therapeutic Apheresis 1: 207-211, 1997.
19. de Dombal FT, Softley A, and International Organization for the Study of Inflammatory Bowel Disease. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. Gut 28: 474-481, 1987.
20. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: Study design and conduct of the study. Gastroenterology 77: 829-842, 1979.
21. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 35: 203-227, 1984.
22. Ip SH, Rittershaus CW, Healey KW, Struzzieiro CC, Hoffman RA, Hansen PW. Rapid enumeration of T lymphocytes by a flow-cytometric immunofluorescence method. Clin Chem 28: 1905-1909, 1982.
23. Irvine EJ, Feagan B, Rochon J, et al. Canadian Crohn's Relapse Prevention Trial Study Group. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 106: 287-296, 1994.
24. Gazzard BG. The quality of life in Crohn's disease. Gut 28: 378-381, 1987 (editorial).
25. Sawada K, Kosaka T, Shimoyama T, et al. Leukocytapheresis therapy with leukocyte removal filter for inflammatory bowel disease: Annual report of the Research Committee of Inflammatory Bowel Disease: The Ministry of Health and Welfare of Japan. 238-241, 1994.
26. Van Wauwe JP, Goossens J, Van Nyen G. Inhibition of lymphocyte proliferation by monoclonal antibody directed against the T3 antigen on human T cells. Cell Immunol 86: 525-534, 1984.
27. Bettens F, Walker C, Gauchat JF, Gauchat D, Wyss T, Pichler WJ. Gauchat Lymphokine gene expression related to CD4 T cell subset (CD45R/ CDw29) phenotype conversion. Eur J Immunol 19: 1569-1574, 1989.
28. + lymphocytes. Nature 339: 152-154, 1989.
29. Riethmuller G, Rieber EP, Kiefersauer S, et al. From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease. Immunol Rev 129: 81-104, 1992.
30. Emmrich J, Seyfarth M, Fleig WE, Emmrich F. Treatment of inflammatory bowel disease with anti-CD4 monoclonal antibody. Lancet 338: 570-571, 1991 (letter).
31. Gajewski TF, Joyce J, Fitch FW. Antiproliferative effect of IFN-gamma in immune regulation. III. Differential selection of TH1 and TH2 murine helper T lymphocyte clones using recombinant IL-2 and recombinant IFN-gamma. J Immunol 143: 15-22, 1989.
32. Cherwinski HM, Schumacher JH, Brown KD, Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th 1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 166: 1229-1244, 1987.
33. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136: 2348-2357, 1986.
34. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342, 1994.